candida
albican
caus
system
infect
typic
immunocompromis
patient
well
mucos
infect
oropharyng
candidiasi
opc
hivinfect
patient
chronic
vagin
infect
azol
antifung
drug
mainstay
manag
infect
howev
increas
use
agent
particularli
fluconazol
treatment
failur
associ
emerg
azoleresist
strain
c
albican
occur
evid
hivaid
patient
receiv
longterm
therapi
opc
azol
bind
inhibit
activ
lanosterol
key
enzym
fungal
ergosterol
biosynthesi
pathway
sever
mechan
resist
azol
describ
c
albican
includ
increas
express
drug
efflux
pump
gene
amino
acid
substitut
target
enzym
due
missens
mutat
gene
possibl
overexpress
importantli
one
isol
resist
may
due
combin
mechan
date
amino
acid
substitut
describ
least
identifi
azoleresist
isol
impact
individu
substitut
howev
vari
may
differ
azol
exampl
substitut
appear
primarili
impact
fluconazol
voriconazol
posaconazol
suscept
effect
substitut
also
addit
strain
substitut
display
higher
mic
azol
compar
substitut
alon
contribut
yet
mutat
resist
uncertain
strain
c
albican
diploid
nucleotid
mutat
may
occur
homozyg
allel
heterozyg
one
allel
substitut
associ
either
type
mutat
resist
suscept
phenotyp
well
defin
nonetheless
sinc
even
singl
nucleotid
polymorph
snp
gene
impact
suscept
contribut
resist
document
chang
import
date
frequenc
clinic
relev
specif
mutat
unselect
azoleresist
isol
poorlydefin
although
one
survey
mutat
contribut
resist
fluconazoleresist
c
albican
hiv
patient
opc
clinic
practic
detect
mutat
potenti
marker
comark
resist
would
assist
identif
track
azoleresist
strain
tradit
dna
sequenc
analysi
standard
identifi
nucleotid
chang
howev
circularis
padlock
probe
recent
shown
reliabl
detect
snp
high
specif
offer
rapid
simpl
altern
sequenc
padlock
probe
compris
three
distinct
region
central
linker
flank
sequenc
complementari
termini
target
sequenc
upon
hybridis
target
probe
end
brought
togeth
join
dna
ligas
form
close
circular
molecul
highli
targetdepend
manner
figur
intens
probe
signal
increas
exponenti
roll
circl
amplif
rca
gener
signal
amplif
within
min
rcabas
assay
success
use
identifi
fungal
pathogen
yet
appli
detect
gene
mutat
associ
antifung
drug
resist
present
report
describ
develop
valid
sensit
rcabas
snp
detect
assay
use
real
time
pcr
detect
point
mutat
c
albican
gene
eight
azoleresist
refer
isol
known
mutat
chosen
target
gene
detect
snp
associ
azol
resist
proof
principl
studi
studi
rca
dna
sequenc
appli
estim
frequenc
seri
mutat
natur
unselect
australian
c
albican
clinic
isol
reduc
suscept
fluconazol
result
compar
obtain
fluconazolesuscept
strain
thirtythre
isol
reduc
suscept
fluconazol
twentyeight
recov
oropharynx
two
vagina
one
bile
sputum
blood
tabl
gene
eight
isol
refer
refer
isol
previous
sequenc
see
method
tabl
remain
clinic
isol
interrog
mutat
tabl
addit
fluconazolesuscept
isol
see
method
categori
susceptibilityresist
cultur
rang
bodi
site
tabl
studi
thu
test
isol
analys
rca
dna
sequenc
one
eight
refer
isol
susceptibledos
depend
sdd
mic
fluconazol
seven
fluconazoleresist
mic
tabl
five
seven
also
resist
voriconazol
mic
six
australian
isol
patient
tabl
fluconazol
mic
sdd
rang
suscept
voriconazol
remain
resist
fluconazol
seven
patient
crossresist
voriconazol
tabl
fluconazolesuscept
isol
also
suscept
voriconazol
tabl
point
mutationspecif
rca
probe
design
base
target
polymorph
site
interest
gene
see
addit
file
assess
sensit
rcabas
assay
rca
initi
perform
serial
dilut
target
templat
pcr
product
see
method
rang
copi
templat
isol
studi
clear
rca
fluoresc
signal
observ
sensit
detect
copi
copi
number
signal
easili
distinguish
background
signal
defin
amplifi
target
templat
mutat
interest
figur
signal
clearli
measur
background
consid
indic
presenc
mutat
capabl
rca
assay
detect
heterozyg
well
homozyg
nucleotid
chang
assess
indirectli
test
abil
detect
specif
mutat
presenc
wildtyp
templat
ie
templat
without
mutat
interest
use
eight
refer
isol
known
mutat
tabl
target
templat
copi
contain
mutat
concentr
backdrop
wildtyp
templat
prepar
mix
templat
abovement
ratio
case
clear
rca
signal
background
observ
dilut
contain
target
templat
figur
result
reproduc
minim
variat
repeat
n
experi
result
demonstr
rca
assay
abl
detect
mutat
high
sensit
presenc
mixtur
dna
sensit
well
requir
detect
heterozyg
nucleotid
chang
expect
ratio
target
templat
mutat
templat
without
mutat
rca
assay
also
highli
specif
amplif
probe
signal
seen
match
templateprob
mixtur
signal
seen
templat
isol
contain
polymorph
target
specif
padlock
probe
use
figur
illustr
typic
padlock
proberca
reaction
use
probe
detect
mutat
isol
tabl
exponenti
increas
fluoresc
signal
readili
interpret
indic
presenc
mutat
refer
isol
produc
signal
background
level
indic
absenc
mutat
known
mutat
refer
isol
correctli
identifi
durat
rca
procedur
h
howev
readili
discern
signal
usual
evid
min
commenc
rca
reaction
gene
test
isol
nonfluconazol
suscept
fluconazolesuscept
amplifi
pcr
bp
fragment
nt
probe
use
rca
subject
dna
sequenc
tabl
sequenc
one
isol
patient
tabl
contain
least
one
missens
mutat
compar
c
albican
atcc
sequenc
genbank
access
result
shown
result
obtain
rca
assay
concord
dna
sequenc
isol
howev
dna
sequenc
identifi
four
addit
amino
acid
substitut
novel
substitut
six
separ
isol
patient
shown
tabl
substitut
detect
rca
correspond
padlock
probe
target
mutat
site
use
studi
thu
point
mutat
result
differ
amino
acid
substitut
detect
among
test
isol
rca
tabl
wherea
substitut
identifi
dna
sequenc
sequenc
identifi
amino
acid
substitut
due
homozyg
nucleotid
polymorph
substitut
present
four
isol
present
three
isol
substitut
n
rare
tabl
note
five
mutat
lead
amino
acid
substitut
present
refer
isol
unit
state
tabl
detect
australian
isol
overal
frequentlyidentifi
substitut
n
isol
follow
n
n
n
nineteen
mutat
cluster
three
region
posit
tabl
sequenti
isol
avail
five
patient
patient
isol
patient
similar
mutat
mic
profil
howev
isol
patient
demonstr
stepwis
increas
voriconazol
mic
parallel
addit
amino
acid
substitut
isol
highest
mic
contain
five
substitut
isol
lowest
mic
contain
three
tabl
convers
patient
one
addit
mutat
present
analysi
second
isol
isol
see
also
tabl
fluconazol
voriconazol
mic
isol
lower
isol
isol
patient
similar
azol
mic
one
differ
mutat
tabl
tabl
mutat
detect
either
rca
sequenc
five
fluconazolesuscept
isol
five
amino
acid
substitut
name
n
isol
n
n
n
n
identifi
tabl
sequenc
homozyg
nucleotid
chang
led
substitut
present
isol
remain
amino
acid
substitut
nucleotid
mutat
heterozyg
case
rca
result
concord
obtain
dna
sequenc
confirm
rcabas
assay
capabl
detect
homozyg
heterozyg
snp
substitut
fifteen
amino
acid
substitut
present
c
albican
isol
display
sdd
suscept
resist
fluconazol
identifi
fluconazolesuscept
strain
tabl
includ
substitut
report
result
reduc
suscept
azol
azol
antifung
wide
use
therapi
prophylaxi
candida
infect
better
understand
mechan
resist
agent
well
earli
detect
resist
essenti
patient
manag
azol
resist
often
due
combin
factor
includ
increas
express
efflux
pump
missens
mutat
latter
link
clinicallyrelev
increas
mic
fluconazol
also
newer
azol
voriconazol
posaconazol
proof
principl
studi
highlight
great
potenti
simpl
rapid
h
highlyspecif
rcabas
snp
detect
assay
readili
perform
clinic
laboratori
detect
andor
surveil
mutat
use
method
identifi
amino
acid
substitut
previouslyuncharacteris
australian
isol
reduc
suscept
fluconazol
sensit
reproduc
rca
assay
establish
determin
abil
detect
known
mutat
refer
isol
tabl
comparison
dna
sequenc
padlock
probe
design
studi
also
accur
identifi
distinguish
snp
within
gene
test
isol
includ
snp
locat
close
togeth
nucleotid
correspond
amino
acid
substitut
respect
addit
file
importantli
identif
mutat
rca
assay
concord
sequenc
case
mutationspecif
probe
use
addit
find
even
though
probe
pair
probe
design
detect
heterozyg
nucleotid
substitut
per
se
rca
assay
detect
chang
isol
contain
mutat
one
allel
demonstr
identif
fluconazolesuscept
isol
larg
number
n
amino
acid
substitut
identifi
test
isol
reduc
susceptibilityresist
fluconazol
agreement
prior
report
one
isol
least
one
often
multipl
missens
mutat
substitut
also
vari
wide
individu
isol
similar
result
report
perea
et
al
detect
mutat
c
albican
isol
high
level
fluconazol
resist
link
resist
contrast
singl
mutat
profil
compris
two
mutat
found
fluconazoleresist
isol
anoth
studi
knowledg
amino
acid
substitut
previous
identifi
among
isol
reduc
suscept
azol
substitut
describ
previous
seen
azoleresist
isol
particular
substitut
known
confer
azol
resist
identifi
three
isol
howev
notabl
substitut
appear
preval
unit
state
europ
rare
australian
isol
nineteen
amino
acid
substitut
includ
present
test
isol
cluster
three
hotspot
region
describ
previous
hot
spot
includ
residu
near
nterminu
protein
region
region
locat
toward
c
terminu
protein
except
substitut
n
isol
howev
computergener
model
locat
close
heme
cofactor
bind
site
substitut
residu
might
expect
impact
neg
bind
azol
contrast
fluconazoleresist
strain
describ
fluconazolesuscept
isol
contain
mutat
substanti
fewer
five
compar
amino
acid
substitut
detect
also
interest
amino
acid
substitut
isol
reduc
azol
suscept
phenotyp
homozyg
wherea
one
except
fluconazolesuscept
isol
present
heterozyg
substitut
two
observ
support
gener
notion
mutat
link
azol
resist
presenc
mutat
suscept
isol
readili
explain
develop
resist
requir
prolong
exposur
azol
howev
previou
studi
attempt
relat
mutat
suscept
isol
fluconazol
exposur
due
retrospect
natur
present
studi
unabl
test
associ
limit
studi
recognis
given
small
number
isol
collect
presenc
mutat
necessarili
function
relat
resist
unabl
determin
clinic
relev
mutat
identifi
sinc
substitut
present
fluconazolesuscept
resist
isol
could
argu
unlik
contribut
reduc
azol
suscept
hand
one
except
identifi
mutat
heterozyg
fluconazolesuscept
isol
find
support
content
loss
heterozygos
diploid
speci
c
albican
step
develop
azoleresist
phenotyp
also
possibl
mani
polymorph
whilst
confer
resist
per
se
may
play
role
increas
level
resist
convers
absenc
substitut
suscept
isol
strongli
suggest
contribut
resist
phenotyp
hypothesi
test
sitedirect
mutagenesi
express
studi
specif
allel
saccharomyc
cerevisia
use
approach
sanglard
cowork
demonstr
substitut
link
azol
resist
among
collect
isol
similar
studi
warrant
determin
new
substitut
associ
resist
test
match
suscept
resist
isol
patient
mutat
may
also
assist
determin
particular
mutat
impact
azol
resist
unfortun
match
isol
avail
present
studi
gener
neither
type
number
mutat
isol
sequenti
obtain
patient
correl
azol
mic
tabl
emphasis
need
assess
addit
gene
understand
contribut
resist
phenotyp
method
detect
polymorph
wellplac
screen
larg
number
isol
differ
sourc
mutat
guid
function
test
isol
resist
studi
demonstr
new
applic
simpl
rcabas
techniqu
rapid
accur
detect
snp
gene
potenti
marker
resist
track
resist
strain
sequencingindepend
method
includ
convent
real
time
pcr
andor
probebas
technolog
eg
molecular
beacon
taqman
probe
result
use
convent
real
time
pcr
wellknown
highlydepend
physic
characterist
platform
molecular
beacon
taqman
probe
method
conveni
avail
form
commerci
kit
although
abl
detect
snp
good
sensit
strict
attent
tm
probe
requir
ensur
adequ
specif
rcabas
method
describ
offer
sever
advantag
amplif
techniqu
ligat
probe
end
dna
ligas
requir
perfectlymatch
targetprob
complex
prevent
nonspecif
amplif
gener
convent
pcr
result
high
specif
also
rapid
h
compar
day
dna
sequenc
follow
dna
extract
whilst
setup
cost
assay
rel
high
aud
per
probe
typic
commerci
batch
probe
provid
suffici
materi
assay
run
cost
estim
aud
per
assay
compar
aud
dna
sequenc
limit
rca
primari
identif
resist
acknowledg
see
howev
techniqu
wellsuit
epidemiolog
tool
high
throughput
screen
commonlyencount
snp
assist
detect
potentiallyresist
strain
track
movement
strain
util
detect
snp
gene
link
azol
resist
c
albcian
encod
transcript
activ
transcript
activ
warrant
consider
conclus
sensit
specif
rcabas
assay
prove
simpl
robust
method
rapid
detect
mutat
show
excel
concord
dna
sequenc
good
potenti
tool
track
specif
strain
identifi
markerscomark
azol
resist
broader
implic
includ
applic
method
studi
oher
gene
mutat
link
azol
resist
c
albican
azol
resist
fungi
aspergillu
fumigatu
mutat
major
mechan
resist
eight
fluconazoleresist
refer
isol
previouslydescrib
mutat
strain
provid
chau
scheringplough
research
institut
kenilworth
new
jersey
tabl
use
valid
rca
assay
two
fluconazolesuscept
isol
strain
atcc
atcc
purchas
american
type
cultur
collect
atcc
rockvil
md
australian
clinic
c
albican
isol
obtain
patient
resist
reduc
suscept
fluconazol
five
patient
patient
isol
recov
separ
occas
fluconazolesuscept
tabl
isol
cultur
collect
clinic
mycolog
laboratori
westmead
hospit
sydney
mycolog
unit
women
children
hospit
adelaid
experiment
work
approv
part
centr
clinic
research
excel
grant
award
nation
health
medic
research
council
australia
grant
approv
scientif
advisori
committe
sydney
west
area
health
servic
research
develop
committe
centr
infecti
diseas
microbiolog
laboratori
servic
westmead
hospit
thu
isol
reduc
fluconazol
suscept
fluconazolesuscept
isol
studi
isol
identifi
c
albican
standard
phenotyp
method
maintain
sabouraud
dextros
agar
requir
mic
fluconazol
voriconazol
pfizer
australia
ryde
australia
determin
atcc
australian
studi
isol
total
n
broth
microdilut
use
clinic
laboratori
standard
institut
clsi
protocol
suscept
test
yeast
candida
parapsilosi
atcc
candida
krusei
atcc
qualiti
control
strain
test
run
mic
endpoint
lowest
concentr
drug
result
growth
inhibit
compar
growth
control
drugfre
well
isol
categoris
suscept
mic
suscept
dosedepend
sdd
mic
resist
mic
fluconazol
accord
clsi
methodolog
fluconazol
voriconazol
mic
refer
isol
report
tabl
dna
extract
perform
describ
previous
nearful
length
gene
bp
amplifi
primer
aggggttccatttgtttaca
ccaaatgatttctgctggtt
beij
augct
biotechnolog
co
ltd
beij
china
preparatori
hybrid
padlock
probe
subsequ
rca
isol
see
sequenc
analysi
atcc
australian
isol
pcr
reaction
contain
templat
dna
forward
primer
revers
primer
dntp
mm
dntp
roch
diagnost
mannheim
germani
hotstar
taq
polymeras
pcr
buffer
qiagen
doncast
victoria
australia
water
total
volum
amplif
perform
mastercycl
gradient
thermocycl
eppendorf
ag
north
ryde
australia
thermal
cycl
condit
min
follow
cycl
final
extens
step
min
pcr
product
visualis
uv
illumin
verifi
amplicon
quantiti
prior
sequenc
analysi
rca
pcr
product
purifi
use
pcr
product
presequenc
kit
usb
corpor
cleveland
ohio
usa
sequenc
use
primer
bigdy
termin
version
cycl
sequenc
kit
abi
prism
genet
analys
appli
biosystem
foster
citi
ca
sequenc
enter
blastn
sequenc
analysi
search
analyz
use
edit
analys
program
biomanag
angi
facil
access
via
http
angisorgau
sequenc
azolesuscept
strain
c
albican
atcc
publish
marich
et
al
genbank
databas
access
use
probe
design
sequenc
chosen
c
albican
atcc
extens
characteris
total
padlock
probe
target
differ
mutat
site
design
addit
file
ten
probe
design
detect
mutat
present
refer
isol
tabl
remain
target
addit
mutat
identifi
azoleresist
isol
probe
nucleotid
nt
length
consist
two
adjac
target
complementari
sequenc
nt
linker
region
figur
optimis
bind
target
dna
probe
design
minimum
secondari
structur
tm
probe
bind
arm
greater
temperatur
use
probe
ligat
see
increas
specif
bind
arm
design
tm
ligat
temperatur
particular
care
attent
paid
linker
region
point
mutationspecif
probe
minimis
similar
mutat
closelyloc
mutat
interest
ii
allow
primer
bind
rca
amplif
probespecif
signal
primer
use
rca
rca
primer
atgggcaccgaagaagca
tm
rca
primer
cgcgcagacacgata
tm
design
specif
bind
linker
region
probe
addit
file
prior
ligat
probe
pcr
product
purifi
remov
excess
buffer
dntp
primer
pcr
product
ad
well
millipor
pcr
purif
plate
pall
life
scienc
ann
arbor
mi
usa
place
vacuum
manifold
min
draw
fluid
small
particl
membran
leav
dna
top
membran
ad
well
process
repeat
plate
remov
vacuum
ad
mixtur
incub
min
transfer
clean
eppendorf
tube
purifi
pcr
product
store
purifi
amplifi
pcr
product
copi
number
dna
templat
dna
calcul
http
wwwurieduresearchgscresourcescndnahtml
mix
u
pfu
dna
ligas
stratagen
la
jolla
ca
usa
padlock
probe
previous
describ
subject
multipl
cycl
ligat
compris
one
cycl
denatur
min
follow
five
cycl
min
ligat
exonucleolysi
perform
remov
unlig
probe
templat
pcr
product
purpos
last
step
reduc
subsequ
ligationindepend
amplif
event
rca
perform
volum
ad
u
exonucleas
exonucleas
iii
new
england
biolab
uk
ligat
mixtur
incub
min
follow
min
exonucleolysi
rca
reaction
perform
volum
contain
u
bst
dna
polymeras
new
england
biolab
deoxynucleotid
triphosph
mix
pmol
rca
primer
dimethyl
sulfoxid
vv
sybr
green
sigmaaldrich
castl
hill
australia
probe
signal
amplifi
incub
min
accumul
dsdna
product
monitor
use
corbett
rotorgenetm
realtim
pcr
machin
corbett
research
mortlak
australia
probe
signal
also
visualis
agaros
gel
verifi
specif
probetempl
bind
sequenc
studi
isol
deposit
genbank
databas
follow
access
number
inclus
inclus
scac
fk
tc
hw
design
research
hw
bw
carri
molecular
work
sequenc
align
mx
particip
sequenc
align
np
fw
de
carri
microbiolog
identif
suscept
experi
pm
help
draft
manuscript
perform
suscept
work
refer
isol
hw
fk
tc
fw
scac
wrote
manuscript
author
approv
final
version
manuscript
